NCT00533208

Brief Summary

To assess the efficacy of MK0524 on seasonal allergies.

Trial Health

100
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
766

participants targeted

Target at P75+ for phase_2

Timeline
Completed

Started Jul 2003

Shorter than P25 for phase_2

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2003

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2003

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2003

Completed
4 years until next milestone

First Submitted

Initial submission to the registry

September 19, 2007

Completed
2 days until next milestone

First Posted

Study publicly available on registry

September 21, 2007

Completed
Last Updated

December 22, 2015

Status Verified

December 1, 2015

Enrollment Period

3 months

First QC Date

September 19, 2007

Last Update Submit

December 21, 2015

Conditions

Seasonal Allergies

Interventions

MK0524DRUG

Eligibility Criteria

Age18 Years - 75 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Person has had at least 2 years of seasonal allergies
  • Person has had a positive skin test to at least 1 of the allergens of the season
  • Person is a non-smoker

You may not qualify if:

  • Person has been hospitalized within the last 4 weeks
  • Person is a female who has had a baby within the last 8 weeks or is still breast-feeding

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Related Publications (1)

  • Philip G, van Adelsberg J, Loeys T, Liu N, Wong P, Lai E, Dass SB, Reiss TF. Clinical studies of the DP1 antagonist laropiprant in asthma and allergic rhinitis. J Allergy Clin Immunol. 2009 Nov;124(5):942-8.e1-9. doi: 10.1016/j.jaci.2009.07.006. Epub 2009 Sep 12.

    PMID: 19748656DERIVED

MeSH Terms

Conditions

Rhinitis, Allergic, Seasonal

Interventions

MK-0524

Condition Hierarchy (Ancestors)

Rhinitis, AllergicRhinitisNose DiseasesRespiratory Tract DiseasesRespiratory HypersensitivityOtorhinolaryngologic DiseasesHypersensitivity, ImmediateHypersensitivityImmune System Diseases

Study Officials

  • Medical Monitor

    Merck Sharp & Dohme LLC

    STUDY DIRECTOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
RANDOMIZED
Masking
DOUBLE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 19, 2007

First Posted

September 21, 2007

Study Start

July 1, 2003

Primary Completion

October 1, 2003

Study Completion

October 1, 2003

Last Updated

December 22, 2015

Record last verified: 2015-12